Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
10:22am, Monday, 29'th Apr 2024
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Thursday, 25'th Apr 2024
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
01:15pm, Friday, 19'th Apr 2024
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Cheap Growth Stocks to Buy During 2Q
11:50am, Tuesday, 16'th Apr 2024
These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with M
Illumina's planned divestment of GRAIL approved by the European Commission
09:00am, Friday, 12'th Apr 2024
SAN DIEGO , April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment pla
EU approves Illumina's plan to divest cancer test maker Grail
05:50am, Friday, 12'th Apr 2024
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
04:33pm, Tuesday, 09'th Apr 2024
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
04:05pm, Tuesday, 09'th Apr 2024
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global
Nasdaq's Nosebleed Section: 3 Expensive Stocks to Sell Before It's Too Late
02:27pm, Friday, 05'th Apr 2024
The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting inv
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
05:00pm, Thursday, 04'th Apr 2024
SAN DIEGO , April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 26'th Mar 2024
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Illumina Stock Zoomed Higher on Thursday
06:37pm, Thursday, 21'st Mar 2024
The gene-sequencing specialist might be able to complete a big-ticket asset buy after all. Its attempt to purchase Grail for $8 billion had been blocked by a European Union regulator.
EU court should back Illumina's appeal against EU review of Grail deal, court adviser says
05:12am, Thursday, 21'st Mar 2024
Europe's top court should back U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1 billion bid for cancer test maker Grail , an adviser to the court
Exclusive: Icahn drops Illumina board challenge threat, sources say
01:57pm, Tuesday, 12'th Mar 2024
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina's board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, according to pe
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
03:00pm, Thursday, 07'th Mar 2024
The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.
